U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524738) titled 'Telemedicine XR-B for Individuals in Jail' on April 06.
Brief Summary: This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release buprenorphine (BRIXADI) using telemedicine prior to release. Individuals will receive weekly XR-B and at least one monthly XR-B injection prior to release. Individuals will be linked to a community treatment provider where they will continue their treatment (buprenorphine) post-release. Participants will be assessed at 1,2-, and 3-months post release
Study Start Date: June 01, 2025
Study Type...